A network of regulatory innovations to improve FDA quality assessments of human drug applications
A network of regulatory innovations brings a holistic approach to improving the submission, assessment, and lifecycle management of pharmaceutical quality information in the U.S. This dedicated effort in the FDA’s Center for Drug Evaluation and Research (CDER) aims to enhance the quality assessment...
Main Authors: | Russie Tran, Grace Fraser, Adam C. Fisher, Sau L. Lee, Ashley Boam, Stelios Tsinontides, Jennifer Maguire, Lawrence X. Yu, Susan Rosencrance, Steven Kozlowski, Don Henry |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2024-06-01
|
Series: | International Journal of Pharmaceutics: X |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2590156724000112 |
Similar Items
-
Availability of Authorizations from EMA and FDA for Age-Appropriate Medicines Contained in the WHO Essential Medicines List for Children 2019
by: Jose-Manuel delMoral-Sanchez, et al.
Published: (2020-04-01) -
FDA regulatory affairs : a guide for prescription drugs, medical devices, and biologics /
by: Pisano, Douglas J, et al.
Published: (2008) -
A Review about Regulatory Status and Recent Patents of Pharmaceutical Co-Crystals
by: Arun Kumar, et al.
Published: (2018-08-01) -
Necessity of strengthening the current clinical regulatory for companion diagnostics: An institutional comparison of the FDA, EMA, and MFDS
by: Su Lim Kang, et al.
Published: (2023-09-01) -
Peculiarities of the Regulatory Status of Radiopharmaceuticals Manufactured in Medical Organisations
by: S. V. Shatik, et al.
Published: (2022-12-01)